• EdU Imaging Kits (Cy3): Precision S-Phase Detection in Cance

  2026-04-25

  EdU Imaging Kits (Cy3) empower researchers with fast, denaturation-free S-phase detection, enabling high-sensitivity cell proliferation assays for cancer and genotoxicity studies. With optimized click chemistry, these kits surpass traditional BrdU methods in preserving cellular integrity and workflow simplicity.

• Hesperadin: Precision Aurora B Kinase Inhibition for Mitotic

  2026-04-24

  Hesperadin from APExBIO empowers precise, ATP-competitive inhibition of Aurora B kinase, redefining spindle assembly checkpoint studies and mitotic progression analyses. Its robust phenotypic outcomes and reproducible workflows make it a premier tool for cancer research and mechanistic dissection of chromosome segregation.

• Alfuzosin HCl in BPH: Clinical Review of Uroselective α1 Ant

  2026-04-24

  This article analyzes the clinical review by Mary Lee on alfuzosin hydrochloride for benign prostatic hyperplasia (BPH), highlighting its functionally uroselective α1-adrenergic antagonism, efficacy in lower urinary tract symptom relief, and favorable cardiovascular safety. The review details protocol-relevant dosing, mechanistic rationale, and practical implications for translational and preclinical BPH research.

• Integrating High-Throughput Screens for Mycobacterial DHFR I

  2026-04-23

  This study introduces a combined high-throughput screening and machine learning framework to identify mechanisms of action and novel inhibitors targeting Mycobacterium tuberculosis dihydrofolate reductase (DHFR). The methodology bridges the gap between phenotypic and target-based discovery, offering a scalable strategy for antibacterial development and precise MoA elucidation.

• Technical Use of Angiotensin I/II (1-5) in RAS Research

  2026-04-23

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of the renin-angiotensin system in hypertension and renal workflows. It is not suitable for unrelated peptide signaling studies due to its specific mechanistic and solubility profile.

• Dextrose (D-glucose) in Tumor Immunometabolism Research

  2026-04-22

  Dextrose (D-glucose) is a cornerstone reagent for dissecting glucose-driven metabolic reprogramming in hypoxic tumor microenvironments. This article delivers protocol-centric guidance, troubleshooting strategies, and translational insights, enabling researchers to harness APExBIO’s high-purity Dextrose for advanced metabolic and immunometabolic investigations.

• Tunicamycin as a Strategic Lever for Translational UPR Resea

  2026-04-22

  This article provides mechanistic and strategic guidance for translational researchers seeking to leverage Tunicamycin, a gold-standard N-glycosylation inhibitor, to dissect endoplasmic reticulum (ER) stress, inflammation, and protein homeostasis pathways. Building on recent findings in cadmium resistance and UPR modulation, it offers evidence-based protocol recommendations, positions Tunicamycin within the competitive landscape, and outlines the translational significance of precise ER stress modulation in disease models.

• Ribonuclease R (20 U/μL): Unveiling Circular RNA’s Role in D

  2026-04-21

  Explore the advanced use of Ribonuclease R (RNase R) (20 U/μL) for circular RNA enrichment and RNA structure analysis in the context of DNA damage and inflammation. This article uniquely connects enzymatic workflows with cutting-edge disease mechanisms, offering actionable insights beyond standard protocols.

• 8-Chloroadenosine: A Benchmark Nucleoside Analog for RNA Res

  2026-04-21

  8-Chloroadenosine is a high-purity nucleoside analog that potently inhibits RNA synthesis, supporting advanced transcriptional regulation and RNA metabolism studies. Its validated quality and mechanistic specificity make it a gold-standard molecular biology reagent for cancer research and lncRNA-targeted workflows. This article details its evidence base, protocol parameters, and limitations, ensuring precise and reproducible experimental use.

• EGCG Nanoparticles Enhance FLASH-RT Efficacy via DNA Damage

  2026-04-20

  This study demonstrates that functionalized EGCG nanoparticles (BENPs) significantly potentiate the antitumor effects of ultra-high dose rate radiotherapy (FLASH-RT) by increasing DNA damage and modulating the immune microenvironment. The findings offer mechanistic insight and translational potential for improving the therapeutic index of FLASH-RT in cancer treatment.

• BIBP 3226 trifluoroacetate: Precision in NPY/NPFF System Res

  2026-04-20

  BIBP 3226 trifluoroacetate empowers researchers to dissect the NPY/NPFF axis in complex disease models, from cardiac arrhythmia to anxiety and analgesia. This guide delivers actionable protocols, troubleshooting insights, and unique translational context—driven by the latest adipose-neural axis findings and APExBIO's robust reagent reliability.

• Mitoxantrone Targets ERα DBD-LBD Interface to Overcome Resis

  2026-04-19

  This study uncovers a novel mechanism by which mitoxantrone, a DNA topoisomerase II inhibitor, disrupts estrogen receptor function in breast cancer by binding at the DBD-LBD interface and promoting proteasomal degradation. The findings highlight a new therapeutic paradigm to counteract endocrine therapy resistance and reframe the utility of mitoxantrone for nuclear receptor research.

• Clozapine N-oxide: Precision Chemogenetic Modulation in Neur

  2026-04-18

  Clozapine N-oxide (CNO) empowers targeted neuronal activity modulation via DREADDs, enabling high-fidelity circuit dissection in AD and beyond. By integrating APExBIO’s high-purity CNO with optimized workflows, researchers achieve reproducible, cell-type-specific control pivotal for next-generation GPCR signaling and memory studies.

• Aconitase Activity Colorimetric Assay Kit: Applied TCA Analy

  2026-04-17

  Unlock sensitive, rapid quantification of mitochondrial function with the Aconitase Activity Colorimetric Assay Kit. APExBIO’s platform empowers oxidative damage and metabolic flexibility studies, streamlining workflows for immunometabolic and stress biomarker research.

• Thiothixene Promotes Macrophage Efferocytosis via Arginase 1

  2026-04-16

  A recent study in Sci Signal demonstrates that the typical antipsychotic agent thiothixene robustly stimulates continual efferocytosis in macrophages through induction of Stra6L and Arginase 1. These findings position thiothixene as a promising candidate for modulating macrophage-mediated clearance of apoptotic and lipid-laden cells, with potential translational implications for diseases characterized by defective efferocytosis.

15352 records 1/1024 page Next 12345 下5页 Last page